Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FSTL3
REST API REST API
Homo sapiens
FSTL3 is differentially expressed in 232 experiments: 127 organism parts: placenta, adrenal gland, ... (125 more);, 187 disease states: normal, lung adenocarcinoma, ... (185 more);, 58 cell types 349 cell lines 33 compound treatments and 61 other conditions.
Synonyms FSRP, FLRG
Orthologs FSTL3_BOVIN (Bos taurus)   Fstl3 (Rattus norvegicus)   Fstl3 (Mus musculus)   FSTL3 (Danio rerio)   FSTL3 (Gallus gallus)   Fs (Drosophila melanogaster)   fstl3 (Xenopus laevis)   FSTL3 (Canis familiaris)   (Compare orthologs)
InterPro Term Prot_Inh_Kazal_2, Fol_N, Prot_inh_Kazal, Follistatin/Osteonectin_EGF
Gene Ontology Term stored secretory granule, negative regulation of activin receptor signaling pathway, protein binding, extracellular space, activin binding, spermatogenesis, male gonad development, extracellular region, positive regulation of transcription from RNA polymerase II promoter, nucleus, negative regulation of BMP signaling pathway, perinuclear region of cytoplasm, regulation of transcription from RNA polymerase II promoter, positive regulation of cell-cell adhesion, kidney development, adrenal gland development, negative regulation of osteoclast differentiation, hemopoietic progenitor cell differentiation, ossification, lung development, negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway, fibronectin binding, neuron projection terminus, cellular response to metal ion
UniProt Accession O95633
Search EB-eye ENSG00000070404
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-19397, ... (33 experiments)

Factor Value U/D Experiments
HepG2
2
E-MTAB-37, E-GEOD-21154
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-5823, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
Kasumi2
1
E-MTAB-37
343 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-20677, ... (33 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-11755, E-GEOD-5099
CXCR5(hi)ICOS(hi) CD4 T cell
1
E-MEXP-750
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
PBMCs
1
E-GEOD-20677
liver cancer
1
E-GEOD-21154
mononuclear
1
E-GEOD-13987
52 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2508, E-MEXP-2069, E-TABM-15, ... (45 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MEXP-231, E-MTAB-62
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
breast cancer
2
E-MTAB-62, E-GEOD-22544
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-MTAB-62, E-GEOD-4290
181 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-5741, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
none
3
8
E-GEOD-5741, E-GEOD-1724, E-GEOD-412, E-GEOD-5824, E-MEXP-1269, ... (11 experiments)
NaOH
1
E-MEXP-2590
sapphyrin PCI-2050
1
E-GEOD-6400
dimethyl sulfoxide
1
E-GEOD-5824
N-nitrosodimethylamine
1
E-GEOD-6907
granulocyte-colony stimulating factor
1
E-GEOD-7400
27 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-1725

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (8 experiments)

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-TABM-147, E-GEOD-19665

Environmental stress
studied in E-GEOD-1518, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-2340

Genotype
studied in E-GEOD-3494, E-GEOD-21750, E-MEXP-421, E-GEOD-2292, E-TABM-321, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-MEXP-1446, E-GEOD-9764, E-MEXP-1273 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (25 experiments)

Infection
studied in E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.478 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM